Zoetis Reports Q1 2025 Growth Amid Currency Challenges and Increased Costs

Company Overview:

Zoetis Inc. (NYSE: ZTS) is a global leader in the animal health industry, focused on developing medicines, vaccines, and diagnostic products for animals.

Latest Income Statement Highlights (Q1 2025):

• Revenue: $2,220 million (up 1% from $2,190 million in Q1 2024)
• Gross Profit: $1,598 million (up from $1,547 million)
• Net Income: $631 million (up 5% from $599 million)
• Earnings Per Share: $1.41 (up from $1.31)
• Dividends: Declared at $0.50 per share, up from $0.432

Positive Aspects:

• Revenue growth driven by price increases and volume from key franchises.
• Reduction in cost of sales as a percentage of revenue from 29.4% to 28.0%.
• Strong gross margins (70-83%) maintained across segments.
• Share repurchase program authorized at $6 billion, with $5.2 billion remaining.

Negative Aspects:

• Challenges from foreign exchange fluctuations adversely impacted revenue growth by approximately 4%.
• Decline in livestock product sales post divestiture of medicated feed additives, contributing to a revenue reduction.
• Selected increases in selling, general, and administrative expenses by 3% due to higher advertising and travel costs.

Key Statistics:

• Cash and Cash Equivalents: $1,721 million (down from $1,987 million)
• Total Assets: $14,098 million (down from $14,237 million)
• Total Liabilities: $9,443 million (down from $9,467 million)
• Long-term Debt: $5,227 million (slightly up from $5,220 million)
• Net Cash Provided by Operating Activities: $587 million (down from $595 million)
• Working Capital: $2,492 million (down from $2,574 million)
• Effective Tax Rate: 22.1%, up from 19.8%

Zoetis is emphasizing innovation in its global animal health solutions, despite facing headwinds from external factors. Investors will need to monitor how effectively the company manages costs and navigates market challenges moving forward.